The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Treatment strategies without access to BCMA- or GPRC5D-directed therapies
Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses treatment strategies for patients with multiple myeloma at first relapse who do not have access to newer BCMA- or GPRC5D-directed therapies. He highlights established antibody, immunomodulatory drug and proteasome inhibitor-based combinations that can provide durable responses, while emphasizing the importance of preserving quality of life and avoiding cross-resistance with therapies that may become available in subsequent lines. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
